Anti-Reverse Phosphorothioate mRNA Cap Analog Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing capped RNA molecules often result in reverse-oriented caps, leading to abnormal behavior and reduced translation efficiency, and existing anti-reverse cap analogs do not simultaneously achieve high stability and translation efficiency.
Innovation Solution
Development of novel anti-reverse phosphorothioate cap analogs with specific phosphorothioate modifications at the α, β, or γ positions, which are resistant to decapping enzymes and exhibit higher affinity for eIF4E, ensuring precise positioning within cap-binding proteins and machinery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional cap analogs are used in RNA synthesis, then the synthesis process is simple, but the caps are frequently incorporated in reverse orientation leading to reduced translation efficiency
Solution Approach 1:
The patent employs asymmetric chemical modifications at specific positions (α, β, or γ) of the cap analog's phosphate groups to create a structurally asymmetric molecule. This asymmetry provides steric and electronic guidance that directs the cap to incorporate exclusively in the correct orientation during RNA synthesis, eliminating reverse incorporation and maximizing translation efficiency.
Solution Approach 2:
The invention introduces localized chemical modifications (phosphorothioate groups with specific stereochemistry) at particular positions within the cap analog structure rather than uniform modification throughout. These localized modifications at α, β, or γ positions create directional recognition elements that ensure proper orientation without affecting the overall simplicity of the synthesis process.
2Reliability
If existing anti-reverse cap analogs are used, then reverse incorporation is reduced, but stability and translation efficiency cannot be simultaneously optimized
Solution Approach 1:
The patent systematically varies chemical parameters including the position (α, β, or γ) of phosphorothioate modifications, stereochemical configuration (R or S), and substitution patterns to optimize both anti-reverse properties and translation efficiency. By changing these molecular parameters, the invention achieves simultaneous optimization of reliability against reverse incorporation and productivity in translation.
Solution Approach 2:
The cap analogs represent composite molecular structures combining multiple functional elements: the base cap structure, phosphorothioate modifications at specific positions, and particular stereochemical configurations. This composite design integrates anti-reverse functionality with enhanced translation efficiency in a single molecular entity.
3Stability of the object's composition
If phosphorothioate modifications are introduced to increase stability, then resistance to degradation improves, but manufacturing complexity increases
Solution Approach 1:
The patent divides the phosphate group into distinct positional segments (α, β, γ) and applies phosphorothioate modifications selectively to specific segments rather than uniformly throughout. This segmentation allows for controlled introduction of stability-enhancing modifications while maintaining manageable synthesis complexity through targeted rather than comprehensive modification.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
New RNA cap analogs are disclosed containing one or more phosphorothioates groups. The analogs also contain modifications at the 2'-O position of 7-methylguanosine that prevent them from being incorporated in the reverse orientation during in vitro synthesis of mRNA and that hence are "anti-reverse cap analogs" (ARCAs). The ARCA modification ensures that the S atom is precisely positioned within the active sites of cap-binding proteins in both the translational and decapping machinery. The new S-ARCA analogs are resistant to in vivo decapping enzymes. Some S-ARCAs have a higher affinity for eIF4E than the corresponding analogs not containing a phosphorothioate group. When mRNAs containing the various S-ARCAs are introduced into cultured cells, some are translated as much as five¬ fold more efficiently than mRNAs synthesized with the conventional analog m7GpppG.